A new targeted therapy called lenvatinib has been shown to improve progression-free survival among patients with advanced thyroid cancer that is not responsive to iodine-131.
from The Medical News http://ift.tt/172QNhy
from The Medical News http://ift.tt/172QNhy
No comments:
Post a Comment